MedTrace Logo

Study is Designed to Assess the Safety and Tolerability of AZD4547 at Increasing Doses in Patients With Advanced Tumours

NCT00979134 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 95

Last updated 2019-03-15

Study results available
· View outcomes & findings →

Summary

This study is primarily designed to assess the safety and tolerability of AZD4547 at increasing doses in patients with advanced solid malignancies and for whom no standard medication options are available. It also assesses the blood levels and action of AZD4547 in the body over a period of time.

Conditions

  • Cancer
  • Advanced Solid Malignancies

Interventions

DRUG

AZD4547

Single dose is followed by washout 5-10 days before multiple dose, and at dose of 80mg twice daily

DRUG

AZD4547

Patients start at a dose of 80 mg twice daily, with no washout

DRUG

AZD4547

Single dose is followed by washout 5-10 days before multiple dose

Sponsors & Collaborators

Principal Investigators

  • Fabrice André, Dr · Institut de cancérologie Gustave Roussy

  • Donal Landers, Dr · AstraZeneca

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
25 Years
Max Age
149 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-10-21
Primary Completion
2014-02-12
Completion
2015-03-05

Countries

  • United States
  • France
  • Germany
  • Italy
  • Netherlands
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00979134 on ClinicalTrials.gov